UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Johnson & Johnson MedTech

J

Johnson & Johnson MedTech

Cardiovascular & MetabolicNew Brunswick, United States
Visit Website

About Johnson & Johnson MedTech

Johnson & Johnson MedTech is one of the world's largest medical technology businesses, operating as the dedicated MedTech segment of Johnson & Johnson following the separation of its consumer health division. With roots stretching back to Johnson & Johnson's founding in 1886, the MedTech division draws on more than a century of surgical and clinical heritage to serve hospitals, surgeons, and healthcare systems across more than 100 countries.

Surgical Innovation & Robotics

The company is a global leader in surgical robotics and digital surgery, anchored by its OTTAVA robotic surgical system, currently in advanced development, and the established Monarch platform for bronchoscopic procedures. Its Ethicon business unit remains one of the most recognised names in sutures, surgical staplers, energy devices, and wound closure, products found in operating theatres worldwide. These portfolios sit at the intersection of hardware, software, and procedural data, reflecting the company's stated strategy of redefining surgery through intelligence and automation.

Orthopaedics & Vision

Johnson & Johnson MedTech holds a leading position in orthopaedics through its DePuy Synthes franchise, which covers joint reconstruction, trauma fixation, spine surgery, and sports medicine. The breadth of this portfolio makes it one of the most comprehensive orthopaedic offerings from any single manufacturer globally. Alongside surgery and orthopaedics, the company operates a substantial vision care business through its Johnson & Johnson Vision unit, producing the Acuvue range of contact lenses, among the best-selling contact lens brands in the world.

Headquartered in New Brunswick, New Jersey, United States, Johnson & Johnson MedTech benefits from parent company Johnson & Johnson's listing on the New York Stock Exchange (ticker: JNJ) and its inclusion in the Dow Jones Industrial Average. Research, manufacturing, and commercial operations span multiple continents, supported by a global workforce that numbers in the tens of thousands within the MedTech segment alone.

The division's focus on cardiovascular intervention, electrophysiology, neurovascular care, and general surgery continues to expand its clinical footprint beyond its established strongholds, positioning it as a broad-spectrum medical technology partner for healthcare providers at every level.

Further information is available at jnjmedtech.com.

Similar Companies

More in Cardiovascular & Metabolic

F

Fortrea

Spun out of Labcorp in 2023, Fortrea entered the contract research organisation market as an independent company with decades of accumulated trial execution expertise behind it. Headquartered in Durham, North Carolina, the organisation operates across more than 90 countries and employs tens of thousands of staff, making it one of the larger CROs active globally from the moment of its launch. Fortrea's core offering centres on clinical development services, spanning Phase I through Phase IV trials across a broad range of therapeutic categories. The company provides site management, patient recruitment, data management, bioanalytical laboratory services, and regulatory affairs support, giving sponsors a largely integrated pathway from early-phase work through post-market studies. Alongside its clinical operations, Fortrea runs an enabling services division that handles functional service provider arrangements, allowing biopharmaceutical clients to access specific capabilities without committing to a full-service model. This flexibility is particularly valued by mid-size and emerging biotechnology sponsors managing constrained timelines and budgets. The company is publicly listed on the Nasdaq stock exchange under the ticker FTRE. Its client base spans large multinational pharmaceutical companies, specialist biotechnology firms, and medical device developers, with therapeutic depth in oncology, central nervous system disorders, infectious disease, cardiovascular medicine, and immunology. Further information is available at fortrea.com.

View profile
G

GE HealthCare

GE HealthCare spun out of General Electric in January 2023 to become an independent, publicly traded medical technology company, bringing with it more than a century of imaging and diagnostics heritage. Listed on the Nasdaq under the ticker GEHC, the company operates across more than 160 countries, serving hospitals, imaging centres, and life-science laboratories worldwide. Imaging & Diagnostics Portfolio The company's core business centres on medical imaging systems, including MRI, CT, PET/CT, X-ray, and ultrasound platforms. Its portfolio spans everything from point-of-care ultrasound devices to large-bore scanners used in oncology and cardiology departments. GE HealthCare's Edison platform provides an open software ecosystem that allows AI-powered applications to be deployed directly on imaging hardware, enabling faster interpretation and workflow automation at the point of care. Patient Care Solutions & Pharmaceutical Diagnostics Beyond capital equipment, GE HealthCare supplies pharmaceutical diagnostics (contrast agents and radiopharmaceutical tracers), patient monitoring systems, and anaesthesia delivery products. Its pharmaceutical diagnostics division manufactures contrast media used in MRI and CT procedures globally, making it one of the largest producers in that segment. The company also provides service contracts, digital health software, and data analytics tools designed to improve operational efficiency in clinical environments. Headquartered in Chicago, Illinois, GE HealthCare employs tens of thousands of people worldwide and maintains manufacturing and research facilities across North America, Europe, and Asia-Pacific. Its customer base includes academic medical centres, community hospitals, outpatient imaging networks, and pharmaceutical manufacturers conducting clinical research. The company organises its business into four reporting segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting the breadth of its involvement across the care pathway from diagnosis through monitoring. Strategic priorities since independence have included expanding AI-enabled software revenue, growing its services business, and extending its presence in emerging markets. Further information is available at gehealthcare.com.

View profile
M

Merck (MSD)

Merck (MSD) created one of the most consequential vaccines in modern medicine, Gardasil, which targets the human papillomavirus strains responsible for the majority of cervical cancer cases worldwide. That achievement is emblematic of a company whose research has shaped global public health across more than a century of operation. Founded in 1891 as a subsidiary of the German Merck Group before becoming an independent entity, Merck operates under the MSD name outside the United States and Canada, giving it one of the more recognisable dual identities in the pharmaceutical industry. Oncology & Keytruda No single product better defines Merck's current position than Keytruda (pembrolizumab), the PD-1 inhibitor that has become the world's best-selling prescription medicine by revenue. Keytruda holds regulatory approvals across a broad range of tumour types, including non-small cell lung cancer, melanoma, head and neck cancers, and several others, cementing Merck's status as one of the dominant forces in cancer immunotherapy. The scale of the Keytruda programme, which spans hundreds of clinical studies in combination and monotherapy settings, reflects a research and development investment that runs to the tens of billions of dollars annually. Vaccines, Infectious Disease & Animal Health Beyond oncology, Merck maintains a substantial vaccines portfolio that extends from childhood immunisation programmes to travel medicine and hospital-acquired infections. The company's antiviral legacy includes longstanding contributions to HIV treatment and, more recently, Lagevrio (molnupiravir) for COVID-19. A dedicated Animal Health division, one of the largest in the world, supplies vaccines and medicines for both livestock and companion animals, underscoring the breadth of the Merck enterprise. Headquartered in Rahway, New Jersey, Merck trades on the New York Stock Exchange under the ticker MRK and employs tens of thousands of people across research, manufacturing, and commercial operations in more than 140 countries. Its pipeline spans infectious diseases, cardiovascular conditions, and several rare diseases, reflecting a deliberate strategy to extend leadership beyond immunology and oncology into areas of significant unmet medical need. Further information is available at merck.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy